News

02. October 2023 Daniel Pfund, Senior Financial Analyst
UBS: the long road to recapturing lost billions
25. September 2023 Olivier Aeschlimann, Senior Financial Analyst
Novartis - Sandoz: the spinoff finally arrives
18. September 2023 Daniel Pfund, Senior Financial Analyst
Swatch Group or affordable luxury
11. September 2023 Hugues Chevalier, Economist
The colossal economic cost of climate inaction
04. September 2023 Olivier Aeschlimann, Senior Financial Analyst
Georg Fischer: strategic acquisition of Finland’s Uponor
26. June 2023 Daniel Pfund, Senior Financial Analyst
Roche obtains FDA approval for its anti-cancer drug Columvi
19. June 2023 Hugues Chevalier, Economist
China: growth stalls
12. June 2023 Olivier Aeschlimann, Senior Financial Analyst
UBS: takeover of CS finalized on June 12
05. June 2023 Daniel Pfund, Senior Financial Analyst
Swiss GDP: first quarter better than expected
30. May 2023 Olivier Aeschlimann, Senior Financial Analyst
Zurich Insurance: encouraging results

Loading...